CytomX Therapeutics (CTMX) Goodwill & Intangibles (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Goodwill & Intangibles data on file, last reported at $1.3 million in Q1 2026.

• Quarterly Goodwill & Intangibles fell 9.76% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 9.76% YoY) and the FY2025 annual result came in at $1.4 million, down 9.46% from the prior year.
• Goodwill & Intangibles slipped to $1.3 million in Q1 2026, from $1.4 million in the prior quarter.
• In the past five years, Goodwill & Intangibles ranged from a high of $1.9 million in Q1 2022 to a low of $1.3 million in Q1 2026.
• A 5-year average of $1.6 million and a median of $1.6 million in 2024 frame the typical range for Goodwill & Intangibles.
• Annual changes were most pronounced in 2022 — Goodwill & Intangibles dropped 7.02% — and 2026, when it declined 9.76%.
• Tracing CTMX's Goodwill & Intangibles over 5 years: stood at $1.8 million in 2022, then retreated by 8.0% to $1.7 million in 2023, then fell by 8.7% to $1.5 million in 2024, then decreased by 9.46% to $1.4 million in 2025, then fell by 2.67% to $1.3 million in 2026.
• The last three Goodwill & Intangibles figures came in at $1.3 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.